Spartan Planning buys 4,783 shares of Merck worth $503K amid strong institutional interest.

Spartan Planning & Wealth Management acquired 4,783 shares of Merck & Co., Inc. valued at about $503,000 in Q4. Other institutional investors also increased their stakes, reflecting confidence in Merck's growth. Despite insider sales, analysts raised price targets, with consensus rating at Moderate Buy and average target price around $127. Merck recently reported strong quarterly earnings and announced a quarterly dividend of $0.85 per share. This activity signals continued investor interest and positive outlook for Merck's biopharmaceutical business.